DNA sequencing for confirmation of rifampin resistance detected by Cepheid Xpert MTB/RIF assay.
DNA sequencing of rpoB and culture-based drug susceptibility results were evaluated for samples referred for confirmation of rifampin resistance detected by the Cepheid Xpert MTB/RIF assay. Silent mutations and mutations associated with low-level resistance were found in the study population. These data support CDC recommendations to confirm Xpert rifampin resistance results.
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia, USA ihk5@cdc.gov.
Allison J
AJ
McAlister
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia, USA.
Jeffrey
J
Driscoll
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia, USA.
Beverly
B
Metchock
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D012321:DNA-Directed RNA Polymerases / Q000235:genetics; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D025202:Molecular Diagnostic Techniques; D012293:Rifampin / Q000494:pharmacology*; D017422:Sequence Analysis, DNA / Q000379:methods*
D000900:Anti-Bacterial Agents; D012321:DNA-Directed RNA Polymerases; C105078:RNA polymerase beta subunit; D012293:Rifampin